Datopotamab deruxtecan
D9260C00003
Phase 2 small_molecule active
Quick answer
Datopotamab deruxtecan for Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active